## Abstract The pattern of HIV‐1 reverse transcriptase and protease mutations conferring resistance to antiretroviral drugs was studied in five treatment‐__naive__ patients and five HIV‐infected patients receiving HAART [two reverse transcriptase inhibitors + one protease inhibitor] for ≥ 1 year. D
Characterization of drug-resistance mutations in HIV-1 isolates from non-HAART and HAART treated patients in Burkina Faso
✍ Scribed by W.M. Nadembega; S. Giannella; J. Simpore; F. Ceccherini-Silberstein; V. Pietra; A. Bertoli; S. Pignatelli; M.C. Bellocchi; J.B. Nikiema; G. Cappelli; A. Bere; V. Colizzi; CP. Perno; S. Musumeci
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 121 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract A cross‐sectional study was undertaken among drug‐naïve HIV patients at the University Hospital in Ouagadougou shortly before and after the introduction of large‐scale antiretroviral therapy (ART) in Burkina Faso. Baseline clinical and virological data as well as protease (PR) and 5′ re
## Abstract Etravirine (ETR) is a non‐nucleoside analogue reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to the development of resistance and with potential activity against __Human immunodeficiency virus type 1__ (HIV‐1) strains resistant to first‐generation NNRTIs. The object